Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide.
High growth potential with excellent balance sheet.
Share Price & News
How has Paion's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PA8's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PA8 exceeded the German Biotechs industry which returned 10.3% over the past year.
Return vs Market: PA8 exceeded the German Market which returned 4.4% over the past year.
Price Volatility Vs. Market
How volatile is Paion's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StWe're Not Worried About Paion's (ETR:PA8) Cash Burn
1 month ago | Simply Wall StIntroducing Paion (ETR:PA8), The Stock That Dropped 26% In The Last Three Years
3 months ago | Simply Wall StHow Many Paion AG (ETR:PA8) Shares Do Institutions Own?
Is Paion undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PA8's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PA8's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PA8 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: PA8 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PA8's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PA8 is overvalued based on its PB Ratio (11x) compared to the DE Biotechs industry average (4.8x).
How is Paion forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PA8 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: PA8 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PA8's is expected to become profitable in the next 3 years.
Revenue vs Market: PA8's revenue (47.8% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: PA8's revenue (47.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PA8's Return on Equity is forecast to be high in 3 years time
How has Paion performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PA8 is currently unprofitable.
Growing Profit Margin: PA8 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PA8 is unprofitable, but has reduced losses over the past 5 years at a rate of 26.6% per year.
Accelerating Growth: Unable to compare PA8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PA8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).
Return on Equity
High ROE: PA8 has a negative Return on Equity (-37.24%), as it is currently unprofitable.
How is Paion's financial position?
Financial Position Analysis
Short Term Liabilities: PA8's short term assets (€22.6M) exceed its short term liabilities (€10.2M).
Long Term Liabilities: PA8's short term assets (€22.6M) exceed its long term liabilities (€25.6K).
Debt to Equity History and Analysis
Debt Level: PA8 is debt free.
Reducing Debt: PA8 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PA8 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PA8 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Paion's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PA8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PA8's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PA8's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PA8's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PA8's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jim Phillips (57yo)
Dr. James Neil Phillips, also known as Jim, MB, ChB, M.D., MBA, serves as Chairman of Management Board and Chief Executive Officer of Paion AG since October 16, 2019. Dr. Phillips serves as the Chief Execu ...
CEO Compensation Analysis
Compensation vs Market: Jim's total compensation ($USD702.25K) is about average for companies of similar size in the German market ($USD697.68K).
Compensation vs Earnings: Insufficient data to compare Jim's compensation with company performance.
|CEO & Chairman of Management Board||0.67yr||€619.95k||no data|
|CFO & Member of Management Board||5.75yrs||€285.13k||no data|
|Chief Development Officer & Member of Management Board||2.5yrs||€285.13k||0.015% €25.3k|
|Vice President of Investor Relations & Public Relations||no data||no data||no data|
Experienced Management: PA8's management team is considered experienced (2.5 years average tenure).
|Chairman of Supervisory Board||10.08yrs||€50.00k||no data|
|Independent Vice Chairman of Supervisory Board||no data||€37.50k||no data|
|Member of Supervisory Board||3yrs||€25.00k||no data|
|Member of Supervisory Board||1.08yrs||€14.17k||no data|
|Independent Member of Supervisory Board||3yrs||€25.00k||no data|
Experienced Board: PA8's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.6%.
Paion AG's company bio, employee growth, exchange listings and data sources
- Name: Paion AG
- Ticker: PA8
- Exchange: XTRA
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €165.700m
- Shares outstanding: 65.49m
- Website: https://www.paion.com
Number of Employees
- Paion AG
- Martinstrasse 10-12
- North Rhine-Westphalia
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PA8||DB (Deutsche Boerse AG)||Yes||Bearer Shares||DE||EUR||Feb 2005|
|PAIO.F||OTCPK (Pink Sheets LLC)||Yes||Bearer Shares||US||USD||Feb 2005|
|PA8||XTRA (XETRA Trading Platform)||Yes||Bearer Shares||DE||EUR||Feb 2005|
|0NF3||LSE (London Stock Exchange)||Yes||Bearer Shares||GB||EUR||Feb 2005|
|PA8D||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Bearer Shares||GB||EUR||Feb 2005|
|PA8||ETLX (Eurotlx)||Yes||Bearer Shares||IT||EUR||Feb 2005|
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/05 22:03|
|End of Day Share Price||2020/06/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.